小剂量阿托伐他汀联合非诺贝特治疗混合型高脂血症临床观察

Clinical Studies on Low-dose Atorvastatin and Fenofibrate for the Treatment of Combined Hyperlipidemia

目的探讨小剂量阿托伐他汀联合非诺贝特治疗混合型高脂血症的疗效及安全性。方法选取混合型高脂血症患者148例,随机均分为2组,观察组晨起口服非诺贝特100mg,晚上服用阿托伐他汀10mg;对照组每晚服用阿托伐他汀20mg。疗程均为8周。观察患者血脂水平变化及不良反应发生情况。结果观察组TC、TG、LDL-C明显降低(P<0.05),HDL-C明显升高(P<0.05);对照组TC、LDL-C明显降低(P<0.05)。与对照组比较,观察组TG水平明显降低(P<0.05),HDL-C水平明显升高(P<0.05)。观察组与对照组临床总有效率分别为79.7%、62.2%(P<0.01)。两组不良反应发生率无统计学差异。结论小剂量阿托伐他汀联合非诺贝特治疗混合型高脂血症疗效较好,不良反应发生率低。

Objective To study the efficacy and safety of low-dose atorvastatin and fenofibrate for the treatment of combined hyperlipidemia. Methods 148 patients with combined hyperlipidemia were randomly divided into two groups. The observation group was treated with oral 100 mg of fenofibrate in the morning,with 10 mg of atorvastatin in the evening. The control group took 20 mg of atorvastatin every night. The treatment lasted 8 weeks. Changes in blood lipid levels and incidence of side effects were observed. Results TC,TG,LDL-C levels decreased significantly（P〈0.05）, and HDL-C level was significantly higher in the observation group（P〈 0.05）. TC,LDL-C decreased significantly in the control group （P〈0.05）. Compared with the control group, TG level was significantly lower （P〈0.05）,and HDL-C level was significantly higher in the observation group （P〈0.05）. The total effective rates of observation group and control group were 79.7% and 62.2% respectively （P〈0.01）. The incidences of adverse reactions between the two groups had no significant differences. Conclusion Low-dose atorvastatin and fenofibrate for the treatment of combined hyperlipidemia is of good effect and low incidence of adverse reactions.